An 'AI scientist', working in collaboration with human scientists, has discovered that combinations of cheap and safe drugs could be effective at treating breast cancer.
Professor David Sebag-Montefiore outlines the profound impact of radiotherapy research. Through global trials and personalised approaches, innovation advances cancer care. Collaborative efforts ensure patient-centred treatments, paving the way for smarter, kinder therapies and a future of precision oncology.
Trevor Graham, Professor of Genomics and Evolution and the Director of the Centre for Evolution and Cancer at the Institute of Cancer Research, London, describes efforts to incorporate genome sequencing for cancer detection and treatment.
Cancer cells are masters of disguise, evading immune destruction through cunning mechanisms. Groundbreaking research reveals a novel tactic: mitochondrial transfer. Cancer cells cripple immune cells by donating their damaged mitochondria, hindering the immune response and fostering tumour growth.
The UK government is investing £82.6 million in groundbreaking research to harness the power of artificial intelligence (AI) to transform cancer care and accelerate drug discovery.
A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient. Researchers identified a RUFY1-RET fusion, highlighting the need for advanced genetic testing to guide treatment strategies and combat evolving resistance.
AI-powered pathology presents the NHS with a unique opportunity to enhance cancer detection. Paige AI explains how its tools can facilitate quicker diagnostics and improve cost efficiency within the UK’s health system.
Tarlatamaba, a new treatment for adult patients with small cell lung cancer (SCLC), has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Infections are the second leading cause of death in cancer patients, after the cancer itself; Zisis Kozlakidis and Shalini Jayasekar Zurn discuss the challenges surrounding the interplay between cancer and antimicrobial resistance (AMR).
A new project is expected to help us understand diseases such as cancer and dementia. A major partnership involving Oxford Nanopore Technologies, UK Biobank, NHS England, Genomics England, and the UK government has made this possible.
The NHS is looking for volunteers as part of the three cancer projects that have been selected as part of the NHS DigiTrials initiative. Almost 150,000 volunteers will take part in these trials to help transform cancer treatment.
